--(BUSINESS WIRE)--Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and other addictions, today announced that EMB-001 was ...

Additionally, our studies of EMB-001in a preclinical model of nicotine ... with statistically significant results versus the positive control, varenicline. We thank our investors for their ...

When the Δinhibition of the EMB-treated sample was larger than 50 ... The screen was validated using the Δinhibition of positive and negative antibiotics with a known mode of action.